Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat
08. März 2021 18:00 ET
|
Novavax, Inc.
GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that...
Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
01. März 2021 16:02 ET
|
Novavax, Inc.
96% vaccine efficacy against original COVID-19 in UK Phase 3 trialVaccine cross-protection demonstrated against both variants circulating in the UK and South AfricaFull enrollment (~30,000...
ノヴァヴァックスと武田がノヴァヴァックスのCOVID-19ワクチン候補のライセンス契約を確定し、武田は日本で第I/Ⅱ相試験を開始
01. März 2021 07:11 ET
|
Novavax, Inc.
日本での製造販売に向けて、武田へのCOVID-19ワクチン技術移転にも合意規制承認申請のため、武田が免疫原性および安全性試験で投薬開始 メリーランド州ゲイザースバーグ発, March 01, 2021 (GLOBE NEWSWIRE) -- 重症感染症の次世代ワクチンを開発するバイオテクノロジー企業ノヴァヴァックス (Novavax, Inc.) (Nasdaq: NVAX)...
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
26. Februar 2021 08:23 ET
|
Novavax, Inc.
Agreement includes COVID-19 vaccine technology transfer to Takeda for local manufacturing and commercialization in JapanTakeda doses first participant in immunogenicity and safety study to support...
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
22. Februar 2021 07:00 ET
|
Novavax, Inc.
PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and Mexico GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing...
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
18. Februar 2021 16:02 ET
|
Novavax, Inc.
Advances joint commitment from Novavax, Serum Institute of India and Gavi to ensure equitable access to NVX-CoV2373 worldwide across low-, middle- and high-income countriesMemorandum of understanding...
Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021
16. Februar 2021 08:00 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it...
Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
15. Februar 2021 20:04 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Feb. 15, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, and SK Bioscience, a...
Novavax und die Regierung der Schweiz geben eine Grundsatzvereinbarung zur Bereitstellung des COVID-19-Impfstoffes bekannt
04. Februar 2021 17:05 ET
|
Novavax, Inc.
GAITHERSBURG, Maryland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das Impfstoffe der nächsten Generation für schwere Infektionskrankheiten...
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
04. Februar 2021 16:05 ET
|
Novavax, Inc.
Rolling reviews have commenced by FDA, MHRA, EMA and Health Canada GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing...